{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T13:55:46Z","timestamp":1785851746946,"version":"3.56.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100030993","name":"Universit\u00e0 della Svizzera italiana","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100030993","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Microbiol Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To describe the epidemiology, clinical characteristics, and serotype distribution of invasive pneumococcal disease (IPD) in adults in Southern Switzerland, and to evaluate the theoretical coverage of higher-valency pneumococcal conjugate vaccines, with particular focus on patients without current vaccination indications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective study included all adults with microbiologically confirmed IPD admitted to four hospitals in Southern Switzerland between January 2019 and December 2024. Clinical data, serotypes, and vaccination status were collected. Theoretical vaccine coverage was calculated for PCV13, PCV15, PCV20, and PCV21. Multivariable logistic regression identified predictors of intensive care unit (ICU) admission and mortality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 210 patients (mean age 69.3\u00a0years), 79 (37.6%) were admitted to the ICU and 18 (8.6%) died. Charlson Comorbidity Index was the only independent predictor of both ICU admission (OR 1.25, 95% CI 1.02\u20131.57) and mortality (OR 2.37, 95% CI 1.54\u20133.64). Serotype 8 was the most frequent isolate (21.0%), followed by serotypes 3 (13.3%) and 4 (9.5%). Only 9.9% of patients had received prior pneumococcal vaccination. Fifty-six patients (26.7%) were aged\u2009&lt;\u200965\u00a0years without comorbidities and had no vaccination indication; 44.6% of these were admitted to the ICU. Serotype 8 accounted for 30.4% of infections in this subgroup. PCV13 and PCV15 would have covered 28.6% and 33.9% of cases in non-eligible adults, whereas PCV20 and PCV21 would have covered 67.9% and 73.2%, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>More than one-quarter of adult IPD occurred in individuals without current vaccination indications, with high rates of severe disease. Higher-valency conjugate vaccines could substantially expand serotype coverage in this population, supporting reconsideration of age-based vaccination strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10096-026-05602-5","type":"journal-article","created":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T13:31:23Z","timestamp":1785850283000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Severe invasive pneumococcal disease beyond current vaccination recommendations: implications for higher-valency vaccines"],"prefix":"10.1007","author":[{"given":"Niccol\u00f2","family":"Ramponi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Barda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Barilaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine","family":"Gallacchi Bouvier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Mueller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Giannini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zain Ahmed","family":"Raza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Merlani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enos","family":"Bernasconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2999-3707","authenticated-orcid":false,"given":"Marco","family":"Bongiovanni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,4]]},"reference":[{"issue":"6","key":"5602_CR1","doi-asserted-by":"publisher","first-page":"e330","DOI":"10.1016\/S1473-3099(24)00740-0","volume":"25","author":"B Ramos","year":"2025","unstructured":"Ramos B, Vadlamudi NK, Han C, Sadarangani M (2025) Future immunisation strategies to prevent Streptococcus pneumoniae infections in children and adults. Lancet Infect Dis 25(6):e330\u2013e344. https:\/\/doi.org\/10.1016\/S1473-3099(24)00740-0","journal-title":"Lancet Infect Dis"},{"issue":"Suppl 10","key":"5602_CR2","doi-asserted-by":"publisher","first-page":"S67","DOI":"10.14309\/ajg.0000000000003641.08","volume":"120","author":"MK Lutz","year":"2025","unstructured":"Lutz MK, Caldera F (2025) Vaccination outcomes and recommendations among older adults in a gastroenterology and hepatology practice. Am J Gastroenterol 120(Suppl 10):S67\u2013S75. https:\/\/doi.org\/10.14309\/ajg.0000000000003641.08","journal-title":"Am J Gastroenterol"},{"issue":"11","key":"5602_CR3","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1111\/imj.16045","volume":"53","author":"CMG Colaco","year":"2011","unstructured":"Colaco CMG, O\u2019Sullivan M, Zhang H et al (2011) Pneumococcal bacteraemia in adults over a 10-year period (2011-2020): a clinical and serotype analysis. Intern Med J 53(11):2028\u20132034. https:\/\/doi.org\/10.1111\/imj.16045","journal-title":"Intern Med J"},{"issue":"4","key":"5602_CR4","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/S1473-3099(24)00588-7","volume":"25","author":"M Garcia Quesada","year":"2025","unstructured":"Garcia Quesada M, Peterson ME, Bennett JC et al (2025) Serotype distribution of remaining invasive pneumococcal disease after extensive use of ten-valent and 13-valent pneumococcal conjugate vaccines (the PSERENADE project): a global surveillance analysis. Lancet Infect Dis 25(4):445\u2013456. https:\/\/doi.org\/10.1016\/S1473-3099(24)00588-7","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"5602_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-75691-5","volume":"10","author":"A L\u00f8chen","year":"2020","unstructured":"L\u00f8chen A, Croucher NJ, Anderson RM (2020) Divergent serotype replacement trends and increasing diversity in pneumococcal disease in high income settings reduce the benefit of expanding vaccine valency. Sci Rep 10(1):18977. https:\/\/doi.org\/10.1038\/s41598-020-75691-5","journal-title":"Sci Rep"},{"issue":"5","key":"5602_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms9051078","volume":"9","author":"ORA Oyewole","year":"2005","unstructured":"Oyewole ORA, Lang P, Albrich WC et al (2005) The impact of pneumococcal conjugate vaccine (PCV) coverage heterogeneities on the changing epidemiology of invasive pneumococcal disease in Switzerland, 2005-2019. Microorganisms 9(5):1078. https:\/\/doi.org\/10.3390\/microorganisms9051078","journal-title":"Microorganisms"},{"issue":"1","key":"5602_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.mm7401a1","volume":"74","author":"M Kobayashi","year":"2024","unstructured":"Kobayashi M, Leidner AJ, Gierke R et al (2024) Expanded recommendations for use of pneumococcal conjugate vaccines among adults aged \u226550 years: recommendations of the Advisory Committee on Immunization Practices - United States, 2024. MMWR Morb Mortal Wkly Rep 74(1):1\u20138. https:\/\/doi.org\/10.15585\/mmwr.mm7401a1","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"36","key":"5602_CR8","doi-asserted-by":"publisher","first-page":"793","DOI":"10.15585\/mmwr.mm7336a3","volume":"73","author":"M Kobayashi","year":"2024","unstructured":"Kobayashi M, Leidner AJ, Gierke R et al (2024) Use of 21-valent pneumococcal conjugate vaccine among U.S. adults: recommendations of the Advisory Committee on Immunization Practices - United States, 2024. MMWR Morb Mortal Wkly Rep 73(36):793\u2013798. https:\/\/doi.org\/10.15585\/mmwr.mm7336a3","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"10","key":"5602_CR9","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1136\/thoraxjnl-2015-206780","volume":"70","author":"A Torres","year":"2015","unstructured":"Torres A, Blasi F, Dartois N, Akova M (2015) Which individuals are at increased risk of pneumococcal disease and why? Impact of COPD, asthma, smoking, diabetes, and\/or chronic heart disease on community-acquired pneumonia and invasive pneumococcal disease. Thorax 70(10):984\u2013989. https:\/\/doi.org\/10.1136\/thoraxjnl-2015-206780","journal-title":"Thorax"},{"issue":"5","key":"5602_CR10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0177113","volume":"12","author":"E Balsells","year":"2017","unstructured":"Balsells E, Guillot L, Nair H, Kyaw MH (2017) Serotype distribution of Streptococcus pneumoniae causing invasive disease in children in the post-PCV era: a systematic review and meta-analysis. PLoS ONE 12(5):e0177113. https:\/\/doi.org\/10.1371\/journal.pone.0177113","journal-title":"PLoS ONE"},{"issue":"3","key":"5602_CR11","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1086\/431521","volume":"192","author":"MH Kyaw","year":"2005","unstructured":"Kyaw MH, Rose CE, Fry AM et al (2005) The influence of chronic illnesses on the incidence of invasive pneumococcal disease in adults. J Infect Dis 192(3):377\u2013386. https:\/\/doi.org\/10.1086\/431521","journal-title":"J Infect Dis"},{"issue":"12","key":"5602_CR12","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1093\/cid\/cit640","volume":"57","author":"M Luj\u00e1n","year":"2013","unstructured":"Luj\u00e1n M, Burgos J, Gallego M et al (2013) Effects of immunocompromise and comorbidities on pneumococcal serotypes causing invasive respiratory infection in adults: implications for vaccine strategies. Clin Infect Dis 57(12):1722\u20131730. https:\/\/doi.org\/10.1093\/cid\/cit640","journal-title":"Clin Infect Dis"},{"issue":"8","key":"5602_CR13","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1093\/cid\/ciab651","volume":"74","author":"P Naucler","year":"2022","unstructured":"Naucler P, Galanis I, Petropoulos A et al (2022) Chronic disease and immunosuppression increase the risk for nonvaccine serotype pneumococcal disease: a nationwide population-based study. Clin Infect Dis 74(8):1338\u20131349. https:\/\/doi.org\/10.1093\/cid\/ciab651","journal-title":"Clin Infect Dis"},{"issue":"1A","key":"5602_CR14","doi-asserted-by":"publisher","first-page":"12S","DOI":"10.1016\/s0002-9343(99)00103-5","volume":"107","author":"SN Taylor","year":"1999","unstructured":"Taylor SN, Sanders CV (1999) Unusual manifestations of invasive pneumococcal infection. Am J Med 107(1A):12S-27S. https:\/\/doi.org\/10.1016\/s0002-9343(99)00103-5","journal-title":"Am J Med"},{"issue":"12","key":"5602_CR15","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1007\/s00134-018-5444-x","volume":"44","author":"JP Bedos","year":"2018","unstructured":"Bedos JP, Varon E, Porcher R et al (2018) Host-pathogen interactions and prognosis of critically ill immunocompetent patients with pneumococcal pneumonia: the nationwide prospective observational STREPTOGENE study. Intensive Care Med 44(12):2162\u20132173. https:\/\/doi.org\/10.1007\/s00134-018-5444-x","journal-title":"Intensive Care Med"},{"issue":"1","key":"5602_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-024-18216-3","volume":"24","author":"Z Di Valerio","year":"2024","unstructured":"Di Valerio Z, La Fauci G, Scognamiglio F et al (2024) Pneumococcal vaccine uptake among high-risk adults and children in Italy: results from the OBVIOUS project survey. BMC Public Health 24(1):736. https:\/\/doi.org\/10.1186\/s12889-024-18216-3","journal-title":"BMC Public Health"},{"issue":"33","key":"5602_CR17","doi-asserted-by":"publisher","first-page":"4911","DOI":"10.1016\/j.vaccine.2022.06.071","volume":"40","author":"B Wyplosz","year":"2022","unstructured":"Wyplosz B, Fernandes J, Sultan A et al (2022) Pneumococcal and influenza vaccination coverage among at-risk adults: a 5-year French national observational study. Vaccine 40(33):4911\u20134921. https:\/\/doi.org\/10.1016\/j.vaccine.2022.06.071","journal-title":"Vaccine"},{"issue":"1","key":"5602_CR18","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2025.2563953","volume":"21","author":"M Chiavarini","year":"2025","unstructured":"Chiavarini M, Boccalini S, Bechini A et al (2025) Pneumococcal vaccination offer and schedules in adults in EU countries: an update. Hum Vaccin Immunother 21(1):2563953. https:\/\/doi.org\/10.1080\/21645515.2025.2563953","journal-title":"Hum Vaccin Immunother"},{"issue":"1","key":"5602_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-023-04347-3","volume":"27","author":"M Mart\u00edn-Cerezuela","year":"2023","unstructured":"Mart\u00edn-Cerezuela M, Aseginolaza-Lizarazu M, Boronat-Garc\u00eda P et al (2023) Severe community-acquired Streptococcus pneumoniae bacterial meningitis: clinical and prognostic picture from the intensive care unit. Crit Care 27(1):72. https:\/\/doi.org\/10.1186\/s13054-023-04347-3","journal-title":"Crit Care"},{"issue":"7","key":"5602_CR20","doi-asserted-by":"publisher","first-page":"4909","DOI":"10.21037\/jtd-2024-2081","volume":"17","author":"T Cheng","year":"2025","unstructured":"Cheng T, Li Y, Gu W et al (2025) Comorbidities and their impact on in-hospital mortality in hospitalized adult patients with bacterial community-acquired pneumonia: a cohort study. J Thorac Dis 17(7):4909\u20134928. https:\/\/doi.org\/10.21037\/jtd-2024-2081","journal-title":"J Thorac Dis"},{"key":"5602_CR21","unstructured":"Swiss Federal Office of Public Health (FOPH). Vaccination recommendations. Available at: https:\/\/www.bag.admin.ch\/bag\/en\/home\/gesund-leben\/gesundheitsfoerderung-und-praevention\/impfungen-prophylaxe.html. Accessed 30 October 2023."},{"issue":"1","key":"5602_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-91234-y","volume":"11","author":"H Chen","year":"2021","unstructured":"Chen H, Matsumoto H, Horita N et al (2021) Prognostic factors for mortality in invasive pneumococcal disease in adult: a system review and meta-analysis. Sci Rep 11(1):11865. https:\/\/doi.org\/10.1038\/s41598-021-91234-y","journal-title":"Sci Rep"},{"issue":"5","key":"5602_CR23","doi-asserted-by":"publisher","first-page":"e65","DOI":"10.1093\/cid\/ciaa1728","volume":"72","author":"Z Amin-Chowdury","year":"2021","unstructured":"Amin-Chowdury Z, Aiano F, Mensah A et al (2021) Impact of the coronavirus disease 2019 (COVID-19) pandemic on invasive pneumococcal disease and risk of pneumococcal coinfection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): prospective national cohort study. England Clin Infect Dis 72(5):e65\u2013e75. https:\/\/doi.org\/10.1093\/cid\/ciaa1728","journal-title":"England Clin Infect Dis"},{"issue":"7","key":"5602_CR24","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1093\/cid\/ciac100","volume":"75","author":"S Perniciaro","year":"2022","unstructured":"Perniciaro S, van der Linden M, Weinberger DM (2022) Reemergence of invasive pneumococcal disease in Germany during the spring and summer of 2021. Clin Infect Dis 75(7):1149\u20131153. https:\/\/doi.org\/10.1093\/cid\/ciac100","journal-title":"Clin Infect Dis"},{"issue":"1","key":"5602_CR25","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2025.2469424","volume":"21","author":"H Maeda","year":"2025","unstructured":"Maeda H, Morimoto K (2025) Global distribution and characteristics of pneumococcal serotypes in adults. Hum Vaccin Immunother 21(1):2469424. https:\/\/doi.org\/10.1080\/21645515.2025.2469424","journal-title":"Hum Vaccin Immunother"},{"issue":"1","key":"5602_CR26","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2025.2521845","volume":"14","author":"C P\u00e9rez-Garc\u00eda","year":"2025","unstructured":"P\u00e9rez-Garc\u00eda C, Gonz\u00e1lez-D\u00edaz A, Domenech M et al (2025) The rise of serotype 8 is associated with lineages and mutations in the capsular operon with different potential to produce invasive pneumococcal disease. Emerg Microbes Infect 14(1):2521845. https:\/\/doi.org\/10.1080\/22221751.2025.2521845","journal-title":"Emerg Microbes Infect"},{"key":"5602_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2024.126543","volume":"44","author":"A Hsiao","year":"2025","unstructured":"Hsiao A, Lewis N, Hansen J et al (2025) Effectiveness of 13-valent pneumococcal conjugate vaccine against vaccine-type invasive pneumococcal disease in older adults. Vaccine 44:126543. https:\/\/doi.org\/10.1016\/j.vaccine.2024.126543","journal-title":"Vaccine"}],"container-title":["European Journal of Clinical Microbiology &amp; Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-026-05602-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10096-026-05602-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-026-05602-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T13:31:25Z","timestamp":1785850285000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10096-026-05602-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,4]]},"references-count":27,"alternative-id":["5602"],"URL":"https:\/\/doi.org\/10.1007\/s10096-026-05602-5","relation":{},"ISSN":["0934-9723","1435-4373"],"issn-type":[{"value":"0934-9723","type":"print"},{"value":"1435-4373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,4]]},"assertion":[{"value":"2 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflicts of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}